ArticleJournal of hepatocellular carcinoma2026
Correlation of Insulin and/or Insulin Secretagogues with the Risk of Hepatocellular Carcinoma and All-Cause Mortality Among Patients with Chronic Hepatitis B and Type 2 Diabetes Mellitus: A Retrospective Cohort Study.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with chronic hepatitis B (CHB) have a higher risk of developing hepatocellular carcinoma (HCC), causing poor prognosis. Type 2 diabetes mellitus (T2DM), a common comorbidity of CHB, further elevates HCC risk. Insulin and insulin secretagogues are commonly used antidiabetic medications (ADMs) that lower blood glucose by elevating circulating insulin levels. This study aimed to explore the association of insulin and/or insulin secretagogues with the risk of HCC and all-cause mortality among patients with CHB and T2DM. Patients and Methods: This study included 696 patients diagnosed with CHB and T2DM between January 2016 and December 2019, who were divided into four groups. Group 1 received insulin and/or insulin secretagogues; Group 2 received no ADMs; Group 3 received other ADMs except for insulin and insulin secretagogues; Group 4 received insulin and/or insulin secretagogues in combination with other ADMs. Cox proportional hazards regression models were constructed to assess the risk of developing HCC and death. Subgroup analysis and sensitivity analysis were conducted to assess the robustness of the findings. Results: Throughout the follow-up period (median 77.5 months for HCC, 80 months for all-cause mortality), Group 1 had a significantly higher incidence of both HCC and all-cause mortality compared with other groups (both P < 0.001). After adjusting for potential covariates, compared with Group 2, Group 1 was associated with a higher risk of developing HCC (HR = 4.42, 95% CI: 1.75-11.17, P = 0.002) and all-cause mortality (HR = 2.46, 95% CI: 1.35-4.50, P = 0.003). Subgroup and sensitivity analyses confirmed robustness. Conclusion: This study found that the use of insulin and/or insulin secretagogues was associated with a higher incidence of HCC and all-cause mortality among patients with CHB and T2DM. However, when combining insulin and/or insulin secretagogues with other types of ADMs, no increased risk was observed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.